Virus purification
Inventors
Barbero Calzado, Jana • Nebenführ, Mario • Schlegl, Robert • Weber, Michael • HEINDL-WRUSS, Jürgen
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
Core Innovation
The independent claim describes a method for purifying infectious virus particles from a crude harvest containing infectious virus particles, non-infectious virus particles, and cell-substrate-derived impurities. The method contacts the harvest with an agent comprising protamine and applies one or more size-exclusion purification methods to obtain a final virus preparation containing infectious particles. The resulting preparation limits residual host-cell DNA, host-cell protein, and virus-particle aggregates, while excluding Japanese encephalitis virus. [procedural detail omitted for safety]
Protamine sulfate treatment selectively reduces non-infectious particles, virus aggregates, and host-cell proteins while reported infectious-virus levels and titers are maintained. Disclosed viral preparations and sequences include Chikungunya virus, Zika virus, and yellow fever virus for use in methods, compositions, and vaccines. The background section is not explicitly described in patent content.
Claims Coverage
The claims identify one independent claim directed to purifying infectious virus particles from a crude harvest, comprising four inventive features.
Protamine treatment of a crude harvest
The method contacts a crude harvest comprising infectious virus particles, non-infectious virus particles, and impurities generated from growing the virus particles on a cell substrate with an agent comprising protamine to obtain a virus preparation comprising infectious virus particles. [procedural detail omitted for safety]
Further purification by size-exclusion methods
The virus preparation is further purified by one or more size-exclusion methods comprising sucrose density gradient centrifugation, a solid-phase matrix with a ligand-activated core and an inactive shell comprising pores, or size exclusion chromatography. [procedural detail omitted for safety]
Specified final preparation composition
The final virus preparation comprises infectious virus particles, less than 100 ng/mL residual host cell DNA, less than 1 ̂g/mL residual host cell protein, and less than 1 ̂g/mL residual virus-particle aggregates.
Exclusion of Japanese encephalitis virus
The claimed virus particles exclude Japanese encephalitis virus.
The claim combines protamine treatment with size-exclusion purification to obtain an infectious-virus preparation meeting defined residual impurity and aggregate limits, while excluding Japanese encephalitis virus.
Stated Advantages
Protamine sulfate treatment selectively depletes non-infectious, immature, and aggregated virus particles, host-cell proteins, and low-molecular-weight impurities while retaining infectious virus titre.
Gradient fractions separate virus from impurities.
The resulting inactivated Zika vaccine is reported to induce neutralizing responses against Asian and African Zika lineages in mice.
Documented Applications
Purification and characterization of Chikungunya virus (including attenuated Δ5nsP3 Chikungunya virus), Zika virus, and yellow fever virus particles for vaccine manufacture.
Preparation of viral antigen, with optional formaldehyde inactivation, and production of an inactivated Zika vaccine evaluated in neutralization plots.
Use of Zika virus genome and envelope glycoprotein E sequences in disclosed methods, compositions, and vaccines.
Interested in licensing this patent?